Cerebral hemorrhagic complications of thrombolytic therapy (Q33794874)

29 July 2017

1 reference

title

Cerebral hemorrhagic complications of thrombolytic therapy (English)

1 reference

29 July 2017

1 reference

Patel SC

1

1 reference

PubMed ID

10598922

29 July 2017

Mody A

series ordinal

2

1 reference

29 July 2017

1 November 1999

1 reference

Progress in Cardiovascular Diseases

29 July 2017

1 reference

29 July 2017

42

1 reference

29 July 2017

3

1 reference

29 July 2017

217-233

1 reference

THE FIBRINOLYTIC ACTIVITY OF HEMOLYTIC STREPTOCOCCI.

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Thrombolytic therapy: current status (1).

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Structural and kinetic comparison of recombinant human single- and two-chain tissue plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Clinical applications of thrombolytic therapy for arterial and graft occlusion

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Expression in Escherichia coli of biologically active enzyme by a DNA sequence coding for the human plasminogen activator urokinase

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Acute cerebral ischemic infarction: a pathophysiologic review and radiologic perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Treatment of acute ischemic stroke. Challenging the concept of a rigid and universal time window

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Cerebral hemorrhagic infarction at autopsy: cardiac embolic cause and the relationship to the cause of death.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Vascular diseases of the brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Ischaemic cerebrovascular diseases in an autopsy series Part 2. Prevalence, location, pathogenesis, and clinical course of cerebral infarcts

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Hemorrhagic infarct of the brain without a reopening of the occluded arteries in cardioembolic stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Hemorrhagic transformation in cerebral embolism

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Thrombolysis in acute ischemic stroke: does it work?

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Hemorrhagic cerebral infarction--a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Thrombolysis with intravenous rtPA in a series of 100 cases of acute carotid territory stroke: determination of etiological, topographic, and radiological outcome factors

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Thrombolytic therapy with streptokinase in acute ischemic stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA)

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Local intra-arterial thrombolysis in acute ischemic stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Local intra-arterial fibrinolytic therapy in acute carotid territory stroke. A pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Acute stroke: usefulness of early CT findings before thrombolytic therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET).

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Local low dose intra-arterial thrombolytic therapy: the risk of stroke or major haemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Thrombolytic therapy: current status (2).

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Intracerebral hemorrhage after fibrinolytic therapy for acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

CT patterns of intracranial hemorrhage complicating thrombolytic therapy for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

Thrombolytic therapy. Agents, indications, and laboratory monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970004-6

7 January 2021

10.1016/S0033-0620(99)70004-6

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10598922